TO Tim Opler Tim Opler Managing Director in Stifel's Global Healthcare Group who advises biotech and pharma companies on M&A, licensing and financings.

“The XBI is down a full 10 percentage points since I started to write that report. I heard pretty negative sentiment. The general sense, from a biotech investor, was that these AI companies need way, way too much money, the US government needs way, way too much money. We saw one AI company with an investment grade go out and raise fixed income money this week at an 8% coupon.”

Biotech Hangout · Health & Longevity · November 2026

“The XBI is down a full 10 percentage points since I started to write that report. I heard pretty negative sentiment. The general sense, from a biotech investor, was that these AI companies need way, way too much money, the US government needs way, way too much money. We saw one AI company with an investment grade go out and raise fixed income money this week at an 8% coupon.” — Tim Opler, Biotech Hangout

Context

Opler had just published an upbeat State of Biotech report, then watched the biotech index slide. He relays why investors think AI's appetite for capital is crowding out biotech. He calls himself an optimist and expects the slump to pass.

Transcript

Biotech Hangout Around 01:07 into the episode
Graig Suvannavejh

…So with that in mind, that's just a high-level view. I'm going to turn things over to Tim, who again puts out a great periodic report called The State of Biotech. His last report came out, I think, last Friday. So I'm going to pass it over to him on some of his insights. So Tim Opler to you.

Tim Opler

Greg, thank you very much. And the report I put out, I think Daphne put a link to it on X. So if you know anyone wants to access it, you can. It's a kind of a long report that really just sort of goes through the whole market. It's very interesting. Bruce Booth also put out a very nice report, which I highly recommend that kind of goes through the whole market as well. And what's nice is the reports are, of course, different. We all have our own perspective. I'm known as being the Oplarbest. So I'm a very optimistic person. And so occasionally I'll go negative on the market. But in that report, I was very upbeat about where biotech is going to go. So that teaches me, right? So since I started to write that report, the XBI is down a full 10 percentage point. So that's actually quite a significant drop in, what, three, four weeks. And so I was talking to some relatively knowledgeable investors in the market yesterday, like what is going on. And I wouldn't say that I heard panic, but I heard like pretty negative sentiment. And, you know, that's obviously not what's going through my head. So like what's happening in the market now? And, you know, we saw the…

Graig Suvannavejh

Thanks, Tim, for that. Maybe just to throw it out there to our group, how are you all thinking about 2027, especially as we come down to the end of 2026? Do we think that it's going to be as robust of an IPO market and a biotech performance perspective? I could see M ⁇ A at a good pace. In fact, it…

Matt Gline

For me, and you would ask me to make a comment about the Anthropic IPO too. I think the main thing that I find difficult to reason through is there's like a whole bunch of biotech specific dynamics. I thought Tim did a really nice job of laying it out. It feels like we are all strapped to a…

Brian Skorney

Yeah, let me just add to what Matt's saying, because I think he's spot on. So I did a, I was thinking the same themes and I did a quick AI search. So take it with a grain of salt. But I said, what percent of the total U.S. stock market publicly traded companies is represented by the companies that…

Speaker names come from our own diarization. The position is estimated from where the line sits in the episode.

More from Biotech Hangout